TRxADE HEALTH Reports First Quarter Revenue Growth of 6% and Q1 2022 Financial Results Continues Nationwide Expansion of Breakthrough Digital Healthcare Services IT Platform TAMPA, FL

HEALTH Reports First Quarter Revenue Growth of 6% and Q1 2022 Financial Results

Nationwide Expansion of Breakthrough Digital Healthcare Services IT Platform

FL, May 9, 2022 - TRxADE HEALTH, INC. (NASDAQ:

MEDS)("TRxADE" or the "Company"), a health services IT company focused on digitalizing the retail pharmacy experience

by optimizing drug procurement, the prescription journey and patient engagement in the U.S., today

announced its financial results for the 2022 first quarter (Q1) ended March 31, 2022.

Quarter 2022 and Subsequent Operational Highlights

continued to expand the TRxADE drug procurement marketplace nationwide, adding 339 new registered members in Q1 2022, bringing the total

registered members to approximately 13,475+ at March 31, 2022.

announced a venture with Exchange Health, LLC, SOSRx, LLC. SOSRx will provide pharmaceutical manufacturers a single platform to optimize

the sale and distribution of their inventory directly to large pharmaceutical buyers across multiple classes of trade. SOSRx opens the

market to short dated, over stock and slow-moving pharmaceuticals that would otherwise be subject to destruction. TRxADE anticipates

growth in 2022 as more progressive manufacturers are expected to address the public need for enhanced medication accessibility and reliable

supply of cost-effective pharmaceuticals.

am pleased with the growth we have experienced in our TRxADE and TRxADE Prime platforms for the first quarter of 2022. We have continued

to drive our business forward, achieving several key milestones in our internal roadmap with a focus on innovation and development through

our various complementary growth opportunities.

new venture, SOSRx, is an exciting addition that provides additional availability to short dated and overstocked drugs, with a goal to

positively impact the public need for cost effective medication.

TRxADE marketplace connects wholesalers and independent pharmacies and our SOSRx marketplace connects the manufacturers and wholesalers.

Both the TRxADE and SOSRx marketplaces deliver radical price transparency, economies of scale and competition that benefit the independent

pharmacies and wholesalers, while expanding the selling potential for such participants.

believe the TRxADE and SOSRx platforms provide the opportunity to deliver more affordable prescription costs for consumers.

is an exciting time for TRxADE, as we continue to position ourselves to create sustainable value for our shareholders," concluded

Mr. Suren Ajjarapu, the Company's Chairman and

Chief Executive Officer.

Quarter 2022 Financial Summary

for the first quarter of 2022, increased 6% to $3.2 million, compared to revenue of $3.1 million in the same quarter last year. The increase

in revenue was primarily due to revenue generated by the TRxADE Platform and TRxADE Prime.

profit in the first quarter of 2022, decreased 4% to $1.3 million, or 41% of revenues, compared to gross profit of $1.4 million, or 45%

of revenues, in the same quarter last year. The decrease in gross profit was primarily attributable to higher costs associated with TRxADE

expenses in the first quarter of 2022 were $2.3 million, compared to $2 million in the same quarter last year. This increase is primarily

due to continued IT initiatives and increased salary and legal expenses.

loss in the first quarter of 2022 was ($1.0) million, or ($0.12) per basic and diluted share outstanding, compared to a net loss of ($0.7)

million, or ($0.08) per basic and diluted share outstanding, in the same quarter last year.

EBITDA, a non-GAAP financial measure, decreased to ($0.7) million for the first quarter of 2022, compared to ($0.5) million in the same

quarter last year. See "Use of Non-GAAP Financial Information" below, and the reconciliation of Adjusted EBITDA to GAAP set

forth at the end of this release.

metrics related to our key performance are as follows:

of March 31, 2022, the TRxADE Platform increased its registered users by 915 or 7.3% compared to March 31, 2021. For the quarter ended

March 31, 2022, new registrations were 339 compared to 223 for the prior period in 2021. As of March 31, 2022, total registered users

increased to 13,475 from 12,560 at March 31, 2021.

table below summarizes the key metrics that management evaluated in relation to the activity on the TRxADE Platform for the three month

period ended March 31, 2022 compared to the same period in 2021:

of March 31, 2022, compared to the same period in 2021, Integra Pharma Solutions, LLC ("TRxADE Prime") increased processed

sales volume over 600% and increased unique buyers on the TRxADE Prime platform by 184%.

table below summarizes the key metrics that management evaluated in relation to the activity for TRxADE Prime for the three month period

ended March 31, 2022, compared to the same period in 2021:

will host a conference call on Monday, May 9, 2022, at 5:00 p.m. Eastern time to discuss TRxADE's first quarter 2022 financial

results. The call will conclude with Q&A from participants. To participate, please use the following information:

2022 Conference Call and Webcast

5:00 p.m. Eastern time

Dial-in: 1-877-425-9470

Dial-in: 1-201-389-0878

dial in at least 10 minutes before the start of the call to ensure timely participation.

playback of the call will be available through June 9, 2022. To listen, call 1-844-512-2921 within the United States or 1-412-317-6671

when calling internationally and enter replay pin number 13728738. A webcast will also be available for 30 days on the IR section of

the TRxADE website or by clicking the webcast link above.

HEALTH, Inc. (NASDAQ: MEDS) is a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug

procurement, the prescription journey and patient engagement in the U.S. The Company operates the TRxADE drug procurement marketplace

serving a total of 13,475+ members nationwide, fostering price transparency and under the Bonum Health brand, offering patient centric

telehealth services. For more information on TRxADE Health, please visit the Company's IR website at investors.trxadehealth.com.

of Non-GAAP Financial Information

addition to our results calculated under generally accepted accounting principles in the United States ("GAAP"), in this

earnings release we also present EBITDA and Adjusted EBITDA which are "non-GAAP financial measures" presented as supplemental

measures of the Company's performance. They are not presented in accordance with GAAP. EBITDA represents net income before interest,

taxes, depreciation and amortization. Adjusted EBITDA is defined as EBITDA before stock-based compensation expense, litigation expense

and loss (gain) on impairment of goodwill. EBITDA and Adjusted EBITDA are presented because we believe they provide additional useful

information to investors due to the various noncash items during the period. EBITDA and Adjusted EBITDA are also frequently used by analysts,

investors and other interested parties to evaluate companies in our industry. We believe these non-GAAP financial measures are useful

to investors both because (1) they allow for greater transparency with respect to key metrics used by management in its financial and

operational decision-making and (2) they are used by our institutional investors and the analyst community to help them analyze the health

of our business. EBITDA and Adjusted EBITDA have limitations as analytical tools, and you should not consider them in isolation, or as

a substitute for analysis of our operating results as reported under GAAP. Some of these limitations are: EBITDA and Adjusted EBITDA

do not reflect cash expenditures, future requirements for capital expenditures, or contractual commitments; EBITDA and Adjusted EBITDA

do not reflect changes in, or cash requirements for, working capital needs; and EBITDA and Adjusted EBITDA do not reflect the significant

interest expense, or the cash requirements necessary to service interest or principal payments, on debt or cash income tax payments.

Although depreciation and amortization are noncash charges, the assets being depreciated and amortized will often have to be replaced

in the future, and EBITDA and Adjusted EBITDA do not reflect any cash requirements for such replacements. Additionally, other companies

in our industry may calculate EBITDA and Adjusted EBITDA differently than TRxADE HEALTH, Inc. does, limiting its usefulness as a comparative

measure. EBITDA and Adjusted EBITDA are not recognized in accordance with GAAP, are unaudited, and have limitations as analytical tools,

and you should not consider them in isolation, or as substitutes for analysis of the Company's results as reported under GAAP.

The Company's presentation of these measures should not be construed as an inference that future results will be unaffected by

unusual or nonrecurring items. We compensate for these limitations by providing a reconciliation of each of these non-GAAP measures to

the most comparable GAAP measure. We encourage investors and others to review our business, results of operations, and financial information

in their entirety, not to rely on any single financial measure, and to view these non-GAAP measures in conjunction with the most directly

comparable GAAP financial measure. For more information on these non-GAAP financial measures, please see the section titled "Reconciliation

of Net Income attributable to TRxADE HEALTH, INC., to Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA) and Adjusted

EBITDA", included at the end of this release.

press release may contain forward-looking statements, including information about management's view of TRxADE's future expectations,

plans and prospects, within the meaning of the federal securities laws, including the safe harbor provisions under The Private Securities

Litigation Reform Act of 1995. In particular, when used in the preceding discussion, the words "may," "could,"

"expect," "intend," "plan," "seek," "anticipate," "believe,"

"estimate," "predict," "potential," "continue," "likely," "will,"

"would" and variations of these terms and similar expressions, or the negative of these terms or similar expressions are

intended to identify forward-looking statements. Any statements made in this news release other than those of historical fact, about

an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and